Global Cystic Fibrosis Therapeutics Market 2016-2026-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Protein Transcription Modulators, Pancreatic Enzyme Products (PEP), Other Therapies

嚢胞性線維症(CF)治療の世界市場2016-2026:嚢胞性線維症膜貫通調節因子(CFTR)モジュレータ、タンパク質転写モジュレータ、膵酵素生成物(PEP)

◆タイトル:Global Cystic Fibrosis Therapeutics Market 2016-2026-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Protein Transcription Modulators, Pancreatic Enzyme Products (PEP), Other Therapies
◆商品コード:VGAIN61206
◆調査・発行会社:visiongain
◆発行日:2016年11月
◆ページ数:191
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Sigle User(1名利用)GBP1,999 ⇒換算¥309,845見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥464,845見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥774,845見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、嚢胞性線維症(CF)治療の世界市場について調査・分析し、嚢胞性線維症(CF)治療の世界市場規模、市場動向、市場予測、市場環境分析、専門家の見解、関連企業情報などを含め、以下の構成でお届けいたします。

The latest report from business intelligence provider visiongain offers comprehensive analysis of the global cystic fibrosis market. Visiongain expects the global cystic fibrosis market to grow at a CAGR of 16.7% from 2016 to 2021. The global cystic fibrosis market is estimated to reach $7.7bn by 2021.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this 191-page report you will receive 113 tables, charts and graphs – all unavailable elsewhere.

The 191 page report provides clear detailed insight into the global cystic fibrosis market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

• Global Cystic Fibrosis market forecasts from 2016-2026

• Cystic Fibrosis submarket forecasts from 2016-2026 covering:
- Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
- Protein Transcription Modulators
- Pancreatic Enzyme Products (PEP)
- Other therapies

• Individual drug revenue forecasts from 2016-2026 by pharmacological classes:

- Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators:
• Orkambi
• Kalydeco
• VX-661 + ivacaftor
• Second corrector/VX-661/ivacaftor

- Protein Transcription Modulators
• Pulmozyme
• QR-010
• Translarna

- Pancreatic Enzyme Products (PEP)
• Ceron

- Other therapies
• Cayston
• TOBI

• Revenue forecasts from 2016-2026 and discussion of relevant trends and developments in the leading national cystic fibrosis market

• Analysis of the key factors driving growth in the global, regional and country level of the Cystic Fibrosis Market from 2016-2026

• Patent and clinical trials information of the marketed and pipeline products for cystic fibrosis

• The dynamic of pricing, patient share and market share of the leading cystic fibrosis drugs in the US and Europe

• Discussion on selected leading companies marketing and developing cystic fibrosis drugs:
- Vertex Pharmaceuticals
- Roche
- AbbVie
- Gilead Sciences
- Novartis

【レポートの目次】

1. Report Overview
1.1 Global Cystic Fibrosis Market Overview
1.2 Why You Should Read This Report
1.3 Structure of the Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Primary Research
1.7.2 Secondary Research
1.7.3 Market Evaluation & Forecasting Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated visiongain Reports
1.10 About visiongain

2. Introduction to the Cystic Fibrosis Market
2.1 An Overview of Cystic Fibrosis
2.2 Genetics Associated With Cystic Fibrosis
2.2.1 CFTR Chromosome Location
2.2.2 CFTR Mutations
2.2.3 Inheritance Pattern
2.3 New-born Screening for Cystic Fibrosis
2.4 Signs and Symptoms
2.4.1 Respiratory Inflammation and Infections
2.4.2 Gastrointestinal Tract Symptoms
2.4.3 Fertility and Reproduction Related Issues
2.5 Diagnosis
2.5.1 Sweat Testing
2.5.2 Nasal Potential Measurements Voltage
2.5.3 Genotyping
2.5.4 Ancillary Testing
2.6 Treatment
2.6.1 Gene Therapy
2.6.2 Symptomatic Treatment
2.6.2.1 Respiratory Care
2.6.2.2 Inhaled Bronchodilators
2.6.2.3 Airway Clearance
2.6.2.4 Antibiotics
2.6.2.5 Lung Transplant
2.6.2.6 Other Treatments
2.7 Prognosis
2.8 Quality of Life
2.9 Epidemiology
2.9.1 Epidemiology Trends in the US
2.9.1.1 Age Distribution of Cystic Fibrosis Patients in the US
2.10 Epidemiology Trends in Europe
2.10.1 Age Distribution of Cystic Fibrosis Patients in Europe
2.11 Epidemiology Trends in Canada
2.12 Epidemiology Trends in RoW
2.13 Epidemiology Trends of F 508 Del Mutations

3. Global Cystic Fibrosis Market 2016-2026
3.1 Cystic Fibrosis Regional Markets 2016-2026
3.1.1 US Cystic Fibrosis Market Forecast 2016-2026
3.1.1 Cost per Patient per Year (US)
3.1.2 Price Increase of Cystic Fibrosis Drugs YoY (US)
3.1.3 Patients Treated by Various Drugs (US)
3.1.4 Patient Share vs Market Share of Top Products (US)
3.2 Europe Cystic Fibrosis Market Forecast 2016-2026
3.3 RoW Cystic Fibrosis Market Forecast 2016-2026
3.3.1 Cystic Fibrosis Japan Market
3.4 Cystic Fibrosis Regional Market Forecast 2016-2026

4. Cystic Fibrosis market – By Pharmaceutical class 2016-2026
4.1 Cystic Fibrosis market – CFTR Modulators 2016-2026
4.1.1 Orkambi (Vertex Pharmaceuticals) market – CFTR Modulators 2016-2026
4.1.2 Kalydeco (Vertex Pharmaceuticals) market – CFTR Modulators 2016-2026
4.1.3 VX-661 + ivacaftor (Royalty Pharma) market – CFTR Modulators 2016-2026
4.1.4 Second corrector/VX-661/ivacaftor (Vertex Pharmaceuticals) market – CFTR Modulators 2016-2026
4.1.5 Cross Comparison of CFTR Modulators Forecast 2016-2026
4.2 Cystic Fibrosis market – Protein Transcription Modulators 2016-2026
4.2.1 Pulmozyme (Roche) market – Protein Transcription Modulators 2016-2026
4.2.2 QR-010 (ProQR Therapeutics) – Protein transcription Modulators 2016-2026
4.2.3 Translarna (PTC Therapeutics) market – CFTR Modulators 2016-2026
4.2.4 Cross Comparison of Protein Transcription Modulators Forecast 2016-2026
4.3 Cystic Fibrosis market – Ceron (AbbVie), Pancreatic enzyme product (PEP) 2016-2026
4.4 Cystic Fibrosis market – Other Therapies 2016-2026
4.4.1 Cayston (Gilead Science) Market Forecast 2016-2026
4.4.2 TOBI (Novartis) Market Forecast 2016-2026
4.5 Cross Comparison of Pharmacological Class Forecast in CF 2016-2026

5. Timeline of Product Launches, Patent analysis and Deal analysis for Key Therapies
5.1 Timeline of US Product Launches – Key Therapies
5.2 Timeline of Europe Product Launches – Key Therapies
5.3 Timeline of Japan Product Launches – Key Therapies
5.4 Patent analysis in Cystic Fibrosis – Key Therapies
5.4.1 Patent analysis of Launched Products – Key Therapies
5.4.2 Patent analysis of Phase 3 Products – Key Therapies
5.4.3 Patent analysis of Phase 2 Products – Key Therapies
5.4.4 Patent analysis of Phase 1 Products – Key Therapies
5.4.5 Patent analysis of pre-clinical and research stage products – Key Therapies
5.5 Deal analysis in Cystic Fibrosis – Key Therapies

6. Product Profiles in Cystic Fibrosis – Key Therapies
6.1 Orkambi (Vertex Pharmaceuticals) Product Profile
6.2 Kalydeco (Vertex Pharmaceuticals) Product Profile
6.3 Pulmozyme (Roche) Product Profile
6.4 Translarna (PTC Therapeutics) Product Profile
6.5 Tezacaftor (Vertex Pharmaceuticals) Product Profile
6.6 Ivacaftor and tezacaftor (Vertex Pharmaceuticals) Combination Product Profile

7. Company Profiles
7.1 Vertex Company Profile
7.1.1 Vertex Company Overview
7.1.2 Vertex Projects Overview
7.1.3 Vertex Recent Deals
7.1.4 Key Product sales (2010-2020)
7.2 Roche Company Profile
7.2.1 Roche Company Overview
7.2.2 Roche Projects Overview
7.2.3 Roche Recent Deals
7.2.4 Roche Key Product sales
7.3 AbbVie Company Profile
7.3.1 AbbVie Company Overview
7.3.2 AbbVie Projects Overview
7.3.3 AbbVie Recent Deals
7.3.4 AbbVie Key Product Sales
7.4 Gilead Sciences Company Profile
7.4.1 Gilead Company Overview
7.4.2 Gilead Projects Overview
7.4.3 Gilead Recent Deals
7.4.3 Gilead Key Product Sales
7.5 Novartis Company Profile
7.5.1 Novartis Company Overview
7.5.2 Novartis Projects Overview
7.5.3 Novartis Recent Deals
7.5.3 Novartis Key Product Sales

8. Qualitative Analysis of the Cystic Fibrosis Market
8.1 Strengths of the Cystic Fibrosis Market
8.2 Weaknesses of the Cystic Fibrosis Market
8.3 Opportunities for the Cystic Fibrosis Market
8.4 Threats for the Cystic Fibrosis Market
8.5 Political Factors Influencing the Cystic Fibrosis Market
8.6 Economical Factors Influencing the Cystic Fibrosis Market
8.7 Social Factors Influencing the Cystic Fibrosis Market
8.8 Technological Factors Influencing the Cystic Fibrosis Market

9. Conclusions
9.1 Cost of Therapies in Cystic Fibrosis
9.2 Patient vs Market Share Trends in Cystic Fibrosis
9.3 Global Cystic Fibrosis Market Trends from 2016 to 2026
9.4 Geographical trends of Cystic Fibrosis Market
9.5 Cystic Fibrosis Market as per Pharmacological Class

10. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form



List of Figures:
Figure 1: Functional Difference in Normal and Cystic Fibrosis Lung Cells
Figure 2: CFTR Chromosome Location
Figure 3: Sweat Testing
Figure 4: Median Predicted Survival Age for Patients Born with Cystic Fibrosis
Figure 5: Worldwide Disease Prevalence of Cystic Fibrosis, 2016 – 2026
Figure 6: US Disease Prevalence of Cystic Fibrosis, 2016 – 2026
Figure 7: Age Distribution of Patients with Cystic Fibrosis in the US, 2016
Figure 8: Age Distribution (%) of Patients with Cystic Fibrosis in the US, 2016
Figure 9: Epidemiology Trends of Patients with Cystic Fibrosis in Europe, 2016 – 2026
Figure 10: Age Distribution of Patients with Cystic Fibrosis in Europe, 2016
Figure 11: Age Distribution (%) of Patients with Cystic Fibrosis in Europe, 2016
Figure 12: Epidemiology Trends of Patients with Cystic Fibrosis in Canada, 2016 – 2026
Figure 13: Prevalence Rate of Cystic Fibrosis by Region, 2016
Figure 14: F 508 Del Mutation Spread US, 2016
Figure 15: F 508 Del Mutation Spread Europe, 2016
Figure 16: Worldwide Cystic Fibrosis Market, 2016-2026
Figure 17: Cystic Fibrosis Regional Market Split, 2016
Figure 18: Cystic Fibrosis Regional Market Split, 2021
Figure 19: Cystic Fibrosis Regional Market Split, 2026
Figure 20: US Cystic Fibrosis Market Forecasts, 2016-2026
Figure 21: Cost per Patient per Year in the US, 2016
Figure 22: YoY Price Growth of Top Cystic Fibrosis Products, 2016
Figure 23: Patients Treated by Various Cystic Fibrosis Drugs, 2016
Figure 24: Patients Share Captured in the US by Various Drugs, 2016
Figure 25: Market Share Captured in the US by Various Drugs, 2016
Figure 26: Europe Cystic Fibrosis Market Forecasts, 2016-2026
Figure 27: RoW Cystic Fibrosis Market Forecasts, 2016-2026
Figure 28: Comparative Cystic Fibrosis Market Forecasts by Region, 2016-2026
Figure 29: CFTR Modulators Market Forecasts, 2016-2026
Figure 30: Orkambi (Vertex Pharmaceuticals) Market Forecasts, 2016-2026
Figure 31: Kalydeco (Vertex Pharmaceuticals) Market Forecasts, 2016-2026
Figure 32: VX-661 + ivacaftor (Royalty Pharma) Market Forecasts, 2016-2026
Figure 33: Second corrector/VX-661/ivacaftor (Vertex Pharmaceuticals) Market Forecasts, 2016-2026
Figure 34: Comparative CFTR Modulators Market Share (%), 2021
Figure 35: Comparative CFTR Modulators Market Share (%), 2026
Figure 36: Comparative CFTR Modulators Market Forecast projections ($m), 2016 – 2026
Figure 37: Protein Transcription Modulators Market Forecasts ($m), 2016-2026
Figure 38: Pulmozyme (Roche) Market Forecasts ($m), 2016-2026
Figure 39: QR-010 Market Forecasts ($m), 2016-2026
Figure 40: Translarna Market Forecasts ($m), 2016-2026
Figure 41: Comparative Protein Transcription Modulators Market Share (%), 2016
Figure 42: Comparative Protein Transcription Modulators Market Share (%), 2021
Figure 43: Comparative Protein Transcription Modulators Market Share (%), 2026
Figure 44: Comparative Protein Transcription Modulators Market Forecast Projections, 2016 – 2026
Figure 45: Ceron (AbbVie) Market Forecasts ($m), 2016-2026
Figure 46: Cayston (Gilead Science) Market Forecasts ($m), 2016-2026
Figure 47: TOBI (Novartis) Market Forecasts ($m), 2016-2026
Figure 48: Comparative Pharmacological Class Market Share (%), 2016
Figure 49: Comparative Pharmacological Class Market Share (%), 2021
Figure 50: Comparative Pharmacological Class Market Share (%), 2026
Figure 51: Comparative Forecast Assessment by Pharmacological Class ($m), 2016 – 2026
Figure 52: Deal Count in CF 2000-2015
Figure 53: Vertex Project Overview by Development Stage
Figure 54: Vertex Project Overview by Therapeutic Area
Figure 55: Vertex Licensing and Acquisition Deals, 2009-2016
Figure 56: Vertex Key Product Sales (Historic and Forecasted), 2010-2020
Figure 57: Roche Project Overview by Development Stage
Figure 58: Roche Deal Count, 2010-2016
Figure 59: Roche Key Product Sales (Historic and Forecasted), 2010-2020
Figure 60: AbbVie Project Overview by Development Stage
Figure 61: AbbVie Deal Count, 2010-2016
Figure 62: AbbVie Key Product Sales (Historic and Forecasted), 2010-2020
Figure 63: Gilead Project Overview by Development Stage
Figure 64: Gilead Deal Count, 2010-2016
Figure 65: Gilead Key Product Sales (Historic and Forecasted), 2010-2020
Figure 66: Novartis Deal Count, 2010-2016
Figure 67: Novartis Key Product Sales (Historic and Forecasted), 2010-2020

【レポートのキーワード】

嚢胞性線維症(CF)治療、嚢胞性線維症膜貫通調節因子(CFTR)モジュレータ、タンパク質転写モジュレータ、嚢胞性線維症(CF)治療用膵酵素生成物(PEP)

★調査レポート[嚢胞性線維症(CF)治療の世界市場2016-2026:嚢胞性線維症膜貫通調節因子(CFTR)モジュレータ、タンパク質転写モジュレータ、膵酵素生成物(PEP)] ( Global Cystic Fibrosis Therapeutics Market 2016-2026-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Protein Transcription Modulators, Pancreatic Enzyme Products (PEP), Other Therapies / VGAIN61206) 販売に関する免責事項
[嚢胞性線維症(CF)治療の世界市場2016-2026:嚢胞性線維症膜貫通調節因子(CFTR)モジュレータ、タンパク質転写モジュレータ、膵酵素生成物(PEP)] ( Global Cystic Fibrosis Therapeutics Market 2016-2026-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Protein Transcription Modulators, Pancreatic Enzyme Products (PEP), Other Therapies / VGAIN61206) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆